-+ 0.00%
-+ 0.00%
-+ 0.00%

On October 8, AstraZeneca announced that Dazhuoyou®, which was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, was officially approved by China's National Drug Administration on September 29, 2026 to treat adult patients with unresectable or metastatic triple-negative breast cancer who are not suitable for treatment with PD-1/PD-L1 inhibitors.

Zhitongcaijing·10/08/2026 08:49:04
Listen to the news
On October 8, AstraZeneca announced that Dazhuoyou®, which was jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, was officially approved by China's National Drug Administration on September 29, 2026 to treat adult patients with unresectable or metastatic triple-negative breast cancer who are not suitable for treatment with PD-1/PD-L1 inhibitors.